Predict your next investment

HEALTHCARE | Medical Facilities & Services / Medical Laboratories & Research
globalcordbloodcorp.com

See what CB Insights has to offer

About Global Cord Blood Corporation

Global Cord Blood Corporation is a life sciences enterprise dedicated to the storage of umbilical cord blood stem cells, leveraging developments in life sciences research and the increasing popularity and rapid advancement of clinical applications using stem cells.

Global Cord Blood Corporation Headquarter Location

Hong Kong

Latest Global Cord Blood Corporation News

Global Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on December 7, 2021

Sep 17, 2021

Intellasia East Asia News 17-Sep-2021 Intellasia | PR Newswire Asia | 6:00 PM HONG KONG, Sept. 17, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company will hold its 2021 annual general meeting of shareholders at its Hong Kong office, located at 48/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong, at 9:00 p.m. Hong Kong Time on December 7, 2021 (8:00 a.m. U.S. Eastern Standard Time on December 7, 2021). Shareholders of record as of October 25, 2021 will be entitled to receive notice of and vote at the annual general meeting. The Company has filed its annual report with the U.S. Securities and Exchange Commission (the "SEC"), which Form 20-F (filed on July 29, 2021) can be accessed via the Investor Center section of the Company's website at http://www.globalcordbloodcorp.com , as well as on the SEC's website at http://www.sec.gov . Shareholders may request a meeting notice, proxy statement and hard copy of the annual report on Form 20-F free of charge, by contacting [email protected] . In view of the enactment of the Prevention and Control of Disease (Prohibition on Group Gathering) Regulation (Cap. 599G of the Laws of Hong Kong), which became effective on March 29, 2020, to promote and maintain social distancing in light of the COVID-19 pandemic, the Company may require shareholders seeking to attend the 2021 annual general meeting to submit temperature testing results and wear approved face coverings. The Company may refuse entry to shareholders who fail to comply with such measures. About Global Cord Blood Corporation Global Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Global Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. For more information, please visit the Company's website at: Safe Harbor Statement This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or the Company's future financial performance. The Company has attempted to identify forward-looking statements by terminology including "anticipates", "believes", "expects", "can", "continue", "could", "estimates", "intends", "may", "plans", "potential", "predict", "should" or "will" or the negative of these terms or other comparable terminology. These statements are only predictions, uncertainties and other factors may cause the Company's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this press release is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company expectations are as of the date this press release is issued, and the Company does not intend to update any of the forward-looking statements after the date this press release is issued to conform these statements to actual results, unless required by law.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Global Cord Blood Corporation

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Global Cord Blood Corporation is included in 1 Expert Collection, including Regenerative Medicine.

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.